MS
RXDX

Maven Securities’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Maven Securities’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,333
Closed -$152K – 1429
2021
Q1 		$152K Buy
+8,333
New +$172K 0.01% 956

Maven Securities's RXDX Position: Q2 2021 in Review

Maven Securities sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2021, closing a stake of 8,333 shares — an estimated $152K sold.

Maven Securities first reported a position in RXDX in Q1 2021 and held it in 1 quarter. The position peaked at $152K in Q1 2021. 49 funds tracked by Wall St. Rank hold RXDX as of Q2 2021.

  • Maven Securities reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 8,333 Prometheus Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $152K.
  • Maven Securities first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Maven Securities's Prometheus Biosciences, Inc. Common Stock position peaked at $152K in Q1 2021.
  • 49 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.